Abstract
Background
We evaluated retrospectively the feasibility and effectiveness of carboplatin-based combination chemotherapy in elderly patients with advanced bladder cancer.
Methods
Forty-seven patients with advanced bladder cancer (33 men and 14 women) and treated at our hospital between August 2004 and December 2011 were enrolled. The average age was 77.1 years (range 70–86 years), the average creatinine clearance was 37.0 ml/min (range 14.5–113.0 ml/min), and the average follow-up period was 17.4 months (range 10–55 months). Twenty-nine patients (61.7 %) were unfit for cisplatin-based chemotherapy. There were 15 recurrent cases after radical surgery and 32 inoperable cases. In this study, the first-line therapy was gemcitabine and carboplatin (GCarbo), with two courses as a set. The second-line therapy was GCarbo and docetaxel (GCarboD) if there was an insufficient response to the first-line therapy.
Results
Of the 47 patients who underwent GCarbo therapy, the response rate was 38.3 % (complete response plus partial response), with 5 and 13 patients exhibiting a complete response and a partial response, respectively. The average response duration was 15.7 months (range 2–42 months). The response rate of the nine patients who received GCarboD was 11.1 %, and the overall median survival was 15.0 months. Adverse events occurred in 30 patients (63.8 %) who underwent GCarbo therapy. Bone marrow suppression was observed in 30 patients (61.7 %), and digestive symptoms were observed in three patients (9.0 %).
Conclusion
Our study demonstrates that GCarbo is a safe and effective combination chemotherapy in elderly patients with advanced bladder cancer. However, the GCarboD regimen appears to have limited effectiveness for nonresponders to GCarbo therapy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Stenzl A, Cowan NC, De Santis M et al (2009) The updated EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol 55(4):815–825
Bellmunt J, Ribas A, Eres N et al (1997) Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma. Cancer 80(10):1966–1972
Bamias A, Moulopoulos LA, Koutras A et al (2006) The combination of gemcitabine and carboplatin as first-line treatment in patients with advanced urothelial carcinoma. A phase II study of the Hellenic Cooperative Oncology Group. Cancer 106(2):297–303
De Santis M, Bellmunt J, Mead G et al (2012) Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol 30(2):191–199
Park JH, Lee SW, Kim HS et al (2013) Combination of gemcitabine and carboplatin as first line treatment in elderly patients or those unfit for cisplatin-based chemotherapy with advanced transitional cell carcinoma of the urinary tract. Cancer Chemother Pharmacol 71(4):1033–1039
Sella A, Kovel S (2012) Combination of gemcitabine and carboplatin in urothelial cancer patients unfit for cisplatin due to impaired renal or cardiac function. Int Braz J Urol 38(1):49–56
Hoshi S, Ohyama C, Ono K et al (2004) Gemcitabine plus carboplatin; and gemcitabine, docetaxel, and carboplatin combined chemotherapy regimens in patients with metastatic urothelial carcinoma previously treated with a platinum-based regimen: preliminary report. Int J Clin Oncol 9(2):125–129
Nogue-Aliguer M, Carles J, Arrivi A et al (2003) Gemcitabine and carboplatin in advanced transitional cell carcinoma of the urinary tract: an alternative therapy. Cancer 97(9):2180–2186
Xu N, Zhang XC, Xiong JP et al (2007) A phase II trial of gemcitabine plus carboplatin in advanced transitional cell carcinoma of the urothelium. BMC Cancer 7:98
Hoschke B, May M, Seehafer M et al (2004) Our experience with 23 consecutive patients on gemcitabine/carboplatin chemotherapy for treatment of metastasized transitional cell carcinoma of the urothelium. Int J Urol 11(7):461–466
Linardou H, Aravantinos G, Efstathiou E et al (2004) Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: phase II study of the Hellenic Co-operative Oncology Group. Urology 64(3):479–484
McCaffrey JA, Hilton S, Mazumdar M et al (1997) Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol 15(5):1853–1857
Tsuruta H, Inoue T, Narita S et al (2011) Combination therapy consisting of gemcitabine, carboplatin, and docetaxel as an active treatment for advanced urothelial carcinoma. Int J Clin Oncol 16(5):533–538
Galsky MD, Hahn NM, Rosenberg J et al (2011) Treatment of patients with metastatic urothelial cancer “unfit” for cisplatin-based chemotherapy. J Clin Oncol 29(17):2432–2438
Calvert AH, Newell DR, Gumbrell LA et al (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7(11):1748–1756
Koie T, Ohyama C, Hashimoto Y et al (2013) Efficacies and safety of neoadjuvant gemcitabine plus carboplatin followed by immediate cystectomy in patients with muscle-invasive bladder cancer, including those unfit for cisplatin: a prospective single-arm study. Int J Clin Oncol 18(4):724–730
Conflict of interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Yoneyama, T., Tobisawa, Y., Yoneyama, T. et al. Carboplatin-based combination chemotherapy for elderly patients with advanced bladder cancer. Int J Clin Oncol 20, 369–374 (2015). https://doi.org/10.1007/s10147-014-0706-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10147-014-0706-2